Part1:Pharmacological activities of Aescigenin
Aescigenin has a wide range of pharmacological activities, including anti-inflammatory, anti-edema, enhancing venous tone, inhibiting gastric acid secretion, scavenging reactive oxygen species, and fighting liver damage. Clinically, it is now mainly used in the treatment of chronic venous insufficiency, cerebral edema, postoperative edema and trauma. In recent years, its anti-tumor effect has gradually attracted the attention of researchers, but there are few related reports, mainly in the in vitro research stage. It is also reported that aescin not only has tumor suppressor effect, but also has the effect of inhibiting tumor metastasis.
Part2：Thyroid cancer threat to human health
Thyroid cancer is the most common malignant tumor of the endocrine system, accounting for more than 90% of malignant tumors in the endocrine glands. The incidence of thyroid cancer is on the rise worldwide, accounting for 2.5% of all malignant tumors in humans.
Part3:The efficacy of Aescigenin
Saponins are an important category of natural products in plants. Aescin is the main active ingredient of the horse chestnut of the horse chestnut family or the traditional Chinese medicine sorrel, and belongs to the triterpenoid saponins. Aescin sodium, a drug widely used clinically, is the sodium salt compound of aescin. Aescin has a wide range of pharmacological activities, including anti-inflammatory, anti-edema, enhancing venous tone, inhibiting gastric acid secretion, scavenging reactive oxygen species, and fighting liver damage. Clinically, it is now mainly used in the treatment of chronic venous insufficiency, cerebral edema, postoperative edema and trauma.
Part4:The first clinical study on escin in thyroid cancer
A recent clinical study by Anhui Medical University in 2017 showed that aescin has a significant therapeutic effect on thyroid cancer, and patients showed good tolerance. This is the first domestic and foreign application of aescin in thyroid cancer. clinical research.
Part5:Clinical research process
In this study, 1120 patients were divided into four groups on average, and they were given a blank reagent as a control and different doses of aescin to evaluate the pharmacokinetics and side effects of aescin. In addition, 2120 patients with thyroid cancer after the use of escin were tested for biomarkers related to disease progression, and the progression-free survival and overall survival were analyzed and evaluated. The escin was administered intravenously for 9 days at 0.6 mg/kg per day. dose, so that the plasma escin concentration remained constant during the treatment period. All patients showed good tolerance. The results showed that escin can significantly reduce the content of thyrotropin, thyroglobulin antibody, thyroglobulin and calcistatin in plasma, prolong the progression-free survival and prolong the progression-free survival of patients with advanced thyroid cancer. overall survival.
Part6:Research result
Only two patients in the study experienced side effects, one developed anemia and the other had elevated alanine aminotransferase. This experiment provides a certain basis for the application of escin in thyroid cancer, and follow-up studies on the efficacy and safety of escin with higher doses and longer use time in thyroid cancer patients are still needed.
